Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 4/20 | 0.31 |
| ▸ | PRKCB | P05771 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262943 | 0.88 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL8181971 | 0.82 | BRD4 (0.46) | JAK2JAK1TYK2DYRK1ADGAT1 | |
| SCHEMBL1504643 | 0.80 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL14749292 | 0.79 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL872289 | 0.79 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL19832096 | 0.78 | KDR (0.37) | DYRK1ADGAT1EGFRIGF1RSRC | |
| SCHEMBL31298152 | 0.78 | KDR (0.37) | DYRK1ADGAT1EGFRIGF1RSRC | |
| SCHEMBL31298196 | 0.77 | DGAT1 (0.34) | TYK2DYRK1ADGAT1EGFRIGF1R | |
| SCHEMBL99248 | 0.75 | JAK2 (0.35) | JAK2JAK1TYK2JAK3DGAT1 | |
| SCHEMBL100496 | 0.73 | LMNA (0.32) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3492468-B1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2022-02-23 | — | — | EP | disclosed |
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3492468-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018019222-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | 张文燕 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.